Etanercept biosimilar (Hanwha Chemical)

依那西普生物类似药（Hanwha Chemical）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Hanwha Chemical)

Drug Alias Name依那西普生物仿制药（Hanwha Chemical）DavictrelMK-8953HD-203

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors

TargetsTumor necrosis factor βTumor necrosis factor α

Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesHanwha Chemical

China Registration ClassN/A

Active CompaniesHanwha Chemical

Inactive CompaniesN/A

Active IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4]

Inactive IndicationsN/A

ATC CodeL04AB01